Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Clin Cancer Res · 2026 · PMC13056244 · PMID 41378992

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

failed to achieve significanceP = 0.054so close (0.05 < p ≤ 0.1)

8.3% for KRAS / BRAF / NRAS WT), though this failed to achieve significance upon formal test for interaction ( P = 0.054; ref. 19 ).

also in 299 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.